Endocare: FDA approves marketing of Cryocare CN2

By Lisa Kerner

Charlotte, N.C., Sept. 12 - The Food and Drug Administration granted marketing approval to Endocare, Inc. for its new Cryocare CN2 System that uses nitrogen to freeze cancerous tumors and tissue.

"Our proprietary Cryocare CN2 System represents a significant advancement in cryoablation because it is more powerful and can get the tumor-ablating job done faster and more effectively than current systems using argon," chairman and chief executive officer Craig T. Davenport said in a news release.

Endocare is a medical device company located in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.